BRIEF-Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial

Vir Biotechnology

Vir Biotechnology

VIR

0.00

May 18 (Reuters) - Vir Biotechnology Inc VIR.O:

  • VIR BIOTECHNOLOGY TO PRESENT COMPLETE WEEK 96 DATA FROM PHASE 2 SOLSTICE CLINICAL TRIAL IN HEPATITIS DELTA AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (EASL) CONGRESS 2026

Source text: ID:nBw5SmxHta

Further company coverage: VIR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.